ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLS5133

A development code. Also written as “QLS5133; Lenvatinib mesylate”, “QLS5133; QL2107; Lenvatinib mesylate” and “QLS5133; Bevacizumab”.

Its studies are mostly in Carcinoma, Renal Cell, led by Qilu Pharmaceutical.

Furthest: phase 2, since Jul 1, 20252 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical22 open or runningphase 2since Jul 1, 2025Jul 1, 2025Jul 2027phase 2 · NCT07061639

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07061639 · 212 planned · China
  2. Nov 6, 2026Phase 2 study in Carcinoma, Renal CellNCT07933419 · 558 planned · China

Ahead

  1. Jul 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07061639
  2. Nov 15, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT07933419

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933419Carcinoma, Renal Cell · China2Not yet recruitingNov 15, 2027558
NCT07061639Advanced Solid Tumors · China2Not yet recruitingJul 2027212

How it is read

Names in the registry

  • “QLS5133; Lenvatinib mesylate”, 1 entry
  • “QLS5133; QL2107; Lenvatinib mesylate”, 1 entry
  • “QLS5133; Bevacizumab”, 1 entry
  • “QLS5133; Platinum; Bevacizumab”, 1 entry
  • “QLS5133; Olaparib; Bevacizumab”, 1 entry

Codes read as this program: QLS5133.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.